Proteasome Inhibitors as a Potential Cause of Heart Failure

File Description SizeFormat 
Proteosomal inhibitor review FINAL.pdfAccepted version506.38 kBAdobe PDFDownload
Title: Proteasome Inhibitors as a Potential Cause of Heart Failure
Author(s): Koulaouzidis, G
Lyon, AR
Item Type: Journal Article
Abstract: Key points • Proteasome inhibitors have become an important drug class in the treatment of multiple myeloma, and currently 3 have received regulatory approval. • In addition to its role in myeloma cells, the proteasome plays a critical role in the myocardium, particularly in the context of cardiac stress. • The growing awareness of the cardiovascular toxicity of proteasome inhibitors is emerging following the phase 3 trials and the transition into real-world practice.
Publication Date: 7-Mar-2017
Date of Acceptance: 1-Mar-2017
URI: http://hdl.handle.net/10044/1/47866
DOI: https://dx.doi.org/10.1016/j.hfc.2016.12.001
ISSN: 1551-7136
Publisher: ELSEVIER
Start Page: 289
End Page: 295
Journal / Book Title: HEART FAILURE CLINICS
Volume: 13
Issue: 2
Copyright Statement: © 2016 Elsevier Inc. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
Proteasome inhibitors
Heart failure
Myocardium Multiple myeloma
RELAPSED MULTIPLE-MYELOMA
ANTICANCER DRUGS
CARDIAC TOXICITY
CARFILZOMIB
DEXAMETHASONE
LENALIDOMIDE
BORTEZOMIB
EXPERIENCE
THERAPY
Heart failure
Multiple myeloma
Myocardium
Proteasome inhibitors
Cardiovascular System & Hematology
Publication Status: Published
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons